Oxford BioMedica - Announcements

News / Announcements 2007

Date	Article

13 December 2007	Oxford BioMedica Initiates Phase I/II Trial of ProSavin^® Gene-Based Treatment for Parkinson?s Disease

10 December 2007	Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax^® Phase III Trial in Renal Cancer

5 December 2007	Oxford Biomedica Wins Scrip’s Licensing Deal of the Year Award

29 November 2007	Oxford BioMedica wins techMARK Award

9 November 2007	Oxford BioMedica Announces Appointment of JPMorgan Cazenove as Sole Corporate Broker and Joint Financial Adviser

26 October 2007	Oxford BioMedica and Sigma-Aldrich Win Key Ruling in Open Bioystems Patent Infringement Dispute

25 October 2007	Oxford BioMedica Responds to Share Price Movement and Reports Business Update

11 September 2007	Oxford BioMedica Plc Interim Results for the Six Months Ended 30 June 2007

11 September 2007	Oxford BioMedica Reaches First Milestone in TroVax^® Collaboration with sanofi-aventis

7 August 2007	Oxford BioMedica Notice of Interim Results for the six months ended 30 June 2007

2 August 2007	Oxford BioMedica: Publication Of TroVax^® Phase II Clinical Trial Data

25 July 2007	Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax^® Phase III Trial in Renal Cancer as Planned

6 July 2007	Oxford BioMedica Secures Rights to Endostatin and Angiostatin Genes for Cancer from Children's Hospital Boston

2 July 2007	Oxford BioMedica and Sigma-Aldrich Issue Joint Licence for LentiVector^® Technology to Major Biotechnology Company

22 June 2007	Oxford BioMedica Wins techMARK Mediscience Award for 'Breakthrough of the Year' for its TroVax^® Licensing Deal with sanofi-aventis

22 June 2007	Oxford BioMedica Viragen Update

18 June 2007	Oxford BioMedica to Present at Piper Jaffray London Health Care Conference

3 June 2007	Oxford BioMedica and sanofi-aventis Report Encouraging New TroVax^® Phase II Trial Results in Renal Cancer

29 May 2007	Oxford BioMedica and Collaborators to Present TroVax^® Phase II Trial Results in Renal Cancer at American Society of Clinical Oncology Meeting

24 May 2007	Oxford BioMedica to present at 2007 FBR Growth Conference

17 May 2007	Oxford BioMedica Announces that Phase II Results with Hi-8^® MEL in Melanoma will be presented at American Association of Immunologists Meeting

8 May 2007	Oxford BioMedica's Collaborators in Transgenics Achieve Expression Breakthrough using OVA^™ System for Therapeutic Protein Production

3 May 2007	Oxford BioMedica Annual General Meeting 2007

1 May 2007	Oxford BioMedica and Collaborators to Present Preclinical Data for RetinoStat^® and StarGen^™ at 2007 ARVO Annual Meeting

29 Mar 2007	Notice of Annual General Meeting

28 Mar 2007	Oxford BioMedica and sanofi-aventis Enter Global Licensing Agreement to Develop and Commercialise TroVax^® for Cancer

12 Mar 2007	Oxford BioMedica to Acquire Oxxon Therapeutics

6 Mar 2007	Oxford BioMedica Plc Preliminary Results For The Year Ended 31 December 2006

27 Feb 2007	Oxford BioMedica: Notice of FY2006 Preliminary Results

1 Feb 2007	Oxford BioMedica Extraordinary General Meeting

24 Jan 2007	Oxford BioMedica Reports Avian Transgenic Milestone: Interferon Alpha Expressed in Eggs

16 Jan 2007	Oxford BioMedica Announces Publication of Avian Transgenic Results in Leading U.S. Scientific Journal

10 Jan 2007	Oxford BioMedica's Phase III Trial of TroVax^® in Renal Cancer Adopted by UK Clinical Trial Network

Website by College Hill - Life Sciences

2008

Archive

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997